KRAS and colorectal carcinoma: Indeed, as discussed above, there are several genetic aberrations, such as mutation in KRAS, NRAS, BRAF, and PIK3CA, loss of PTEN, and amplification of HER2/MET, which have been associated with the de novo resistance to anti-EGFR therapies in CRC.